Patents by Inventor William Christian Fanslow, III
William Christian Fanslow, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11866508Abstract: The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies and bispecific antibodies which specifically bind to mesothelin. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies, including methods of treating and preventing cancer or other hypoproliferative disorders and related disorders by administering such antigen binding proteins and antibodies to a subject in need of such treatment.Type: GrantFiled: January 6, 2021Date of Patent: January 9, 2024Assignee: AMGEN INC.Inventors: William Christian Fanslow, III, Carl Kozlosky, Jean Gudas
-
Publication number: 20210380714Abstract: The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies and bispecific antibodies which specifically bind to mesothelin. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies, including methods of treating and preventing cancer or other hypoproliferative disorders and related disorders by administering such antigen binding proteins and antibodies to a subject in need of such treatment.Type: ApplicationFiled: January 6, 2021Publication date: December 9, 2021Inventors: William Christian Fanslow, III, Carl Kozlosky, Jean Gudas
-
Patent number: 10919975Abstract: The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies and bispecific antibodies which specifically bind to mesothelin. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies, including methods of treating and preventing cancer or other hypoproliferative disorders and related disorders by administering such antigen binding proteins and antibodies to a subject in need of such treatment.Type: GrantFiled: September 6, 2018Date of Patent: February 16, 2021Assignee: AMGEN INC.Inventors: William Christian Fanslow, III, Carl Kozlosky, Jean Marie Gudas
-
Patent number: 10266604Abstract: The present invention relates to CD27L antigen binding proteins, such an antibodies, polynucleotides encoding said CD27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with CD27L expression.Type: GrantFiled: January 10, 2017Date of Patent: April 23, 2019Assignee: AMGEN INC.Inventors: John M. Delaney, William Christian Fanslow, III, Chadwick Terence King
-
Publication number: 20190055316Abstract: The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies and bispecific antibodies which specifically bind to mesothelin. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies, including methods of treating and preventing cancer or other hypoproliferative disorders and related disorders by administering such antigen binding proteins and antibodies to a subject in need of such treatment.Type: ApplicationFiled: September 6, 2018Publication date: February 21, 2019Inventors: William Christian Fanslow, III, Carl Kozlosky, Jean Marie Gudas
-
Patent number: 10100121Abstract: The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies and bispecific antibodies which specifically bind to mesothelin. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies, including methods of treating and preventing cancer or other hypoproliferative disorders and related disorders by administering such antigen binding proteins and antibodies to a subject in need of such treatment.Type: GrantFiled: April 28, 2016Date of Patent: October 16, 2018Assignee: AMGEN INC.Inventors: William Christian Fanslow, III, Carl Kozlosky, Jean Marie Gudas
-
Publication number: 20170267775Abstract: The present invention relates to CD27L antigen binding proteins, such an antibodies, polynucleotides encoding said CD27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with CD27L expression.Type: ApplicationFiled: January 10, 2017Publication date: September 21, 2017Inventors: John M. Delaney, William Christian Fanslow, III, Chadwick Terence King
-
Publication number: 20160340440Abstract: The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies and bispecific antibodies which specifically bind to mesothelin. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies, including methods of treating and preventing cancer or other hypoproliferative disorders and related disorders by administering such antigen binding proteins and antibodies to a subject in need of such treatment.Type: ApplicationFiled: April 28, 2016Publication date: November 24, 2016Inventors: William Christian Fanslow, III, Carl Kozlosky, Jean Marie Gudas
-
Publication number: 20150201588Abstract: Disclosed is an autologous non-human mammalian model system derived from induced pluripotent stem (iPS) cells. Also disclosed are methods of differentiating non-human primate iPS cells, which can result in populations of cells enriched for SOX2+ or PDX1+ foregut-like cells, for CDX2+ hindgut-like cells, for CD34+ hematopoietic progenitor-like cells, or epithelial-like cells. Also disclosed is a non-human primate containing an autologous cell type of interest, which is differentiated in vitro from an induced pluripotent stem cell reprogrammed from a primary somatic cell. Methods of monitoring exogenously introduced cells within a non-human mammal are also disclosed.Type: ApplicationFiled: February 22, 2013Publication date: July 23, 2015Applicant: AMGEN INC.Inventors: Carl Alexander Kamb, Helen Y. Kim, Sungeun Kim, William Christian Fanslow, III
-
Patent number: 8987422Abstract: The present invention relates to CD27L antigen binding proteins, such an antibodies, polynucleotides encoding said CD27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with CD27L expression.Type: GrantFiled: September 20, 2012Date of Patent: March 24, 2015Assignee: Amgen Inc.Inventors: John M. Delaney, William Christian Fanslow, III, Chadwick Terence King
-
Publication number: 20140004121Abstract: The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies and bispecific antibodies which specifically bind to mesothelin. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies, including methods of treating and preventing cancer or other hypoproliferative disorders and related disorders by administering such antigen binding proteins and antibodies to a subject in need of such treatment.Type: ApplicationFiled: June 25, 2013Publication date: January 2, 2014Inventors: William Christian Fanslow, III, Carl Kozlosky, Jean Marie Gudas
-
Publication number: 20130078237Abstract: The present invention relates to CD27L antigen binding proteins, such an antibodies, polynucleotides encoding said CD27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with CD27L expression.Type: ApplicationFiled: September 20, 2012Publication date: March 28, 2013Inventors: John M. DELANEY, William Christian FANSLOW, III, Chadwick Terence KING
-
Publication number: 20100215572Abstract: The invention is directed to LDCAM as a purified and isolated protein, the DNA encoding the LDCAM, host cells transfected with cDNAs encoding LDCAM, processes for preparing LDCAM polypeptides and compositions and methods for treating utilizing LDCAM polypeptides.Type: ApplicationFiled: May 4, 2010Publication date: August 26, 2010Applicant: Immunex CorporationInventors: Peter Robert BAUM, William Christian Fanslow, III
-
Patent number: 7741115Abstract: The invention is directed to LDCAM as a purified and isolated protein, the DNA encoding the LDCAM, host cells transfected with cDNAs encoding LDCAM, processes for preparing LDCAM polypeptides and compositions and methods for treating utilizing LDCAM polypeptides.Type: GrantFiled: July 16, 2008Date of Patent: June 22, 2010Assignee: Immunex CorporationInventors: Peter Robert Baum, William Christian Fanslow, III
-
Patent number: 7659385Abstract: The invention is directed to LDCAM as a purified and isolated protein, the DNA encoding the LDCAM, host cells transfected with cDNAs encoding LDCAM, processes for preparing LDCAM polypeptides and compositions and methods for treating utilizing LDCAM polypeptides.Type: GrantFiled: July 14, 2008Date of Patent: February 9, 2010Assignee: Immunex CorporationInventors: Peter Robert Baum, William Christian Fanslow, III
-
Publication number: 20090155845Abstract: The invention is directed to LDCAM as a purified and isolated protein, the DNA encoding the LDCAM, host cells transfected with cDNAs encoding LDCAM, processes for preparing LDCAM polypeptides and compositions and methods for treating utilizing LDCAM polypeptides.Type: ApplicationFiled: July 14, 2008Publication date: June 18, 2009Applicant: Immunex CorporationInventors: Peter Robert Baum, William Christian Fanslow, III
-
Publication number: 20090011499Abstract: The invention is directed to LDCAM as a purified and isolated protein, the DNA encoding the LDCAM, host cells transfected with cDNAs encoding LDCAM, processes for preparing LDCAM polypeptides and compositions and methods for treating utilizing LDCAM polypeptides.Type: ApplicationFiled: July 16, 2008Publication date: January 8, 2009Applicant: Immunex CorporationInventors: Peter Robert Baum, William Christian Fanslow, III
-
Patent number: 7402655Abstract: The invention is directed to LDCAM as a purified and isolated protein, the DNA encoding the LDCAM, host cells transfected with cDNAs encoding LDCAM, processes for preparing LDCAM polypeptides and compositions and methods for treating utilizing LDCAM polypeptides.Type: GrantFiled: February 6, 2001Date of Patent: July 22, 2008Assignee: Immunex CorporationInventors: Peter Robert Baum, William Christian Fanslow, III